|
Nov 10 2022
Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update
|
|
Sep 26 2022
Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson’s Disease Patient-Derived Dopaminergic Neurons
|
|
Sep 20 2022
Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer
|
|
Sep 19 2022
Gain Therapeutics Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson’s Disease
|
|
Sep 08 2022
Gain Therapeutics to Present Data at Upcoming Medical Meetings
|
|
Sep 06 2022
Gain Therapeutics To Participate At The H.C. Wainwright 24th Annual Global Investment Conference
|
|
Aug 08 2022
Gain Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Business Update
|
|
Aug 04 2022
Gain Therapeutics to Participate at the 2022 BTIG Biotechnology Conference
|
|
Jun 02 2022
Gain Therapeutics to Participate at the Jefferies Healthcare Conference
|
|
May 18 2022
Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference
|
|
May 16 2022
Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update
|
|
May 11 2022
Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium
|
|
May 06 2022
Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at XXVII IAPRD World Congress
|
|
Apr 26 2022
Gain Therapeutics to Participate in the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
|
|
Apr 12 2022
Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at the 2022 Synuclein Meeting
|
|
Mar 29 2022
Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid and Sphingolipid Biology Gordon Research Conference
|
|
Mar 24 2022
Gain Therapeutics, Inc. Reports Full Year 2021 Financial Results and Business Update
|
|
Mar 15 2022
Gain Therapeutics Presents Positive Data on its Structurally Targeted Allosteric Regulators in both Parkinson’s and Alzheimer’s Disease at the AD/PD 2022 Conference
|
|
Mar 01 2022
Gain Therapeutics Announces Participation in Upcoming Investor and Scientific Conferences
|
|
Feb 08 2022
Gain Therapeutics Presents Preclinical Data on its Structurally Targeted Allosteric Regulators in GBA1 Gaucher Disease at the WORLDSymposium 2022
|
|
Feb 04 2022
Gain Therapeutics Outlines Key Objectives for 2022 Following its Inaugural R&D Day
|
|
Jan 31 2022
Gain Therapeutics Announces Additional Details on its February 4th Virtual R&D Day
|
|
Jan 18 2022
Gain Therapeutics Announces R&D Day Event and Participation in Upcoming Conferences
|
|
Jan 06 2022
Gain Therapeutics to Participate at the H.C. Wainwright Bioconnect Virtual Conference
|
